Summary
Although hypertensive therapy has had spectacular successes, there is now an important trend away from mere control of blood pressure to the attempt to normalize the cardiac and vascular accompaniments of the disease, such as left ventricular hypertrophy and medial hypertrophy of resistance arterioles. New agents may need to be developed to cope with these specific aims. The costs of development should not inhibit these important goals.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Robertson JIS. The 1985 trials of hypertension treatment. In: Hansson L (ed.) Hypertension Yearbook. London: Gower Academic Journals, 1986;3–25.
Robertson JIS. The large studies in hypertension: What have they shown?Br J Clin Pharm 1987;24:3–145.
Robertson JIS. Hypertension and its treatment in the elderly.Clin Exp Hypertens 1989, in press.
Medical Research Council Working Party. M.R.C. trial of treatment of mild hypertension: Principal results.Br Med J 1985;291:97–104.
Lindholm L. Hypertension and its risks: Epidemiological studies in Swedish primary health care. PhD Thesis, University of Lund, 1984.
Samuelsson O. Hypertension in middle-aged men.Acta Med Scand 1985;(Suppl 102):1–79.
Isles CG, Walker L, Beevers DG, Brown I, Cameron H, Clarke J, Hawthorne V, Hole D, Lever AF, Robertson JWK, Wapshaw JA. Mortality in patients of the Glasgow Blood Pressure Clinic.J Hypertens 1986;4:141–156.
Robertson JIS. Hypertension and coronary risk: Possible adverse effects of antihypertensive drugs.Am Heart J 1987;114:S1051–1054.
Robertson JIS, Hansson L. How well is hypertension treated?J Hypertens 1986;4 (Suppl 6):638–641.
Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure.Lancet 1987;2:581–583.
Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood pressure and myocardial infarction.Br Med J 1988;297:1227–1230.
Waller PC, Isles CG, McInnes GT. Coronary flow reserve and the J curve.Br Med J 1988;297:1606.
Cruickshank JM. Coronary flow reserve and the J curve.Br Med J 1989;298:457–458.
Kaplan NM. The J curve and other problems with therapy.Am J Hypertens 1989;2:132–133.
Hansson L. J curve relation between diastolic blood pressure and myocardial infarction.Br Med J 1989;298:52.
Spence JD. Haemodynamic aspects of the pathogenesis of atherosclerosis. In: Lie KI, Schalekamp MA, van Zwieten PA (eds). Hypertension and coronary atherosclerosis: Prevention and intervention. Amstelveen: BRL, 1988:47–57.
Robertson JIS, Birkenäger WH. The heart in hypertension: Mechanical and humoral factors. In: Safar M (ed).The Heart in Hypertension. Boston: Martinus Nijhoff, 1989.
Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment.Br Med J 1988;296:320–331.
Freis ED, Papademetriou V. How dangerous are diuretics?Drugs 1985;30:469–474.
Ramsay LE. Diuretics.Side Effects of Drugs Annual 1987;11:193–202.
Moser M. In defense of traditional antihypertensive therapy.Hypertension 1988;12:324–326.
Rawlins MD. Alfred Nobel and the drug hunters: Pharmacologists have won many Nobel prizes.Br Med J 1988;297:1628.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robertson, J.I.S. Should the costs of development inhibit research into new antihypertensive drugs?. Cardiovasc Drug Ther 3, 757–759 (1989). https://doi.org/10.1007/BF01857627
Issue Date:
DOI: https://doi.org/10.1007/BF01857627